The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study
Authors:
- Carlo CarnaghiCCCarlo Carnaghi
- Armando SantoroASArmando Santoro
- Lorenza RimassaLorenza Rimassa
- Roberto DociRDRoberto Doci
- Riccardo RosatiRRRiccardo Rosati
- Vittorio PediciniVPVittorio Pedicini
- Giuseppe GulloGGGiuseppe Gullo
- Monica ZuradelliMZMonica Zuradelli
- Giovanni AbbadessaGAGiovanni Abbadessa
- Emanuela MorenghiEMEmanuela Morenghi
- Ilaria MarconIMIlaria Marcon
- Isabella GarassinoIGIsabella Garassino
- 11 May 2007
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 25 (5) , 479-485
Abstract
Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2–63) and the median overall survival (OS) 21 months (range 6–63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.Keywords
This publication has 19 references indexed in Scilit:
- Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal CancerJournal of Clinical Oncology, 2005
- Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the Fédération Nationale des Centres de Lutte Contre le CancerJournal of Clinical Oncology, 2005
- Hepatic Artery Infusion Chemotherapy for Metastatic Colorectal Cancer to the Liver at the Lahey ClinicAmerican Journal of Clinical Oncology, 2004
- Hepatic arterial chemotherapy for colorectal cancer liver metastases: a review of advances in 2003Current Opinion in Oncology, 2004
- Laparoscopic Placement of Hepatic Arterial Pumps: A True Advance or a Lot of Effort for a Procedure with a Diminishing Role?Annals of Surgical Oncology, 2004
- An Update on Hepatic Arterial Infusion Chemotherapy for Colorectal CancerThe Oncologist, 2003
- Phase I/II Study of Hepatic Arterial Therapy With Floxuridine and Dexamethasone in Combination With Intravenous Irinotecan As Adjuvant Treatment After Resection of Hepatic Metastases From Colorectal CancerJournal of Clinical Oncology, 2003
- Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trialThe Lancet, 2003
- Current treatment for liver metastases from colorectal cancerWorld Journal of Gastroenterology, 2003
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989